A Phase II Trial of Tildrakizumab for Prevention of Acute Graft-Versus-Host Disease
Latest Information Update: 08 Jul 2024
At a glance
- Drugs Tildrakizumab (Primary)
- Indications Graft-versus-host disease
- Focus Therapeutic Use
Most Recent Events
- 24 Jun 2024 Status changed from active, no longer recruiting to completed.
- 25 Jan 2024 Planned End Date changed from 1 Jan 2025 to 1 Jun 2024.
- 25 Jan 2024 Planned primary completion date changed from 1 Jan 2024 to 1 Jun 2024.